pd-l1 inhibitor incb099318
Generic: PD-L1 Inhibitor INCB099318
pd-l1 inhibitor incb099318: 1 clinical trial tracked.
pd-l1 inhibitor incb099318 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about pd-l1 inhibitor incb099318, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Clinical Trial Registry Records (1)
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Select Advanced Solid Tumors
Primary endpoint: Number of treatment-emergent adverse events
Interventionalopen105 targetStarted 2021-03Completion 2024-0824 sites · Belgium, Denmark, Finland, Norway…Incyte Corporation